ShareValue scores for DMAAR: Valuation 53, Quality 50, Growth 50, Health 52.
DMAARNASDAQ
Drugs Made In America Acquisition Corp. Rights
$0.16
(0.00%)
DMAARNASDAQ
Drugs Made In America Acquisition Corp. Rights
$0.16(0.00%)
Loading chart...
Sentiment
Verdicts
Value:Fair Value
Quality:Moderate
Growth:Moderate
Health:Moderate
Verdicts
Fundamental Rating
Value Trap Risk
Expected Return
6% to 17%
Rating
Trap Risk
Return
6% to 17%
Valuation
53
Fair Value
Price vs Value
Quality
50
Moderate
Business Strength
Growth
50
Moderate
Revenue & Earnings
Health
52
Moderate
Financial Stability
Momentum
100
Bullish
Price Trend
Company Details
About
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.
Sector
IndustryN/A
ExchangeNASDAQ
Market Cap$3M
P/E RatioN/A
Dividend YieldNone
Sector Rank#778
Score Analysis
AI Investment Thesis
Data as of:Aug 7, 2026
|Last calculated:Aug 7, 2026